New Immune-Targeting drug could boost stomach cancer treatment
NCT ID NCT07673887
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding the experimental drug ASP2138 to standard chemotherapy and immunotherapy (pembrolizumab) helps people with a specific type of advanced stomach or gastroesophageal junction cancer live longer without their disease worsening. The study enrolls adults whose tumors are HER2-negative and have a protein called CLDN18.2. Participants are randomly assigned to receive either ASP2138 plus standard treatment or a placebo plus standard treatment, and neither they nor their doctors know which group they are in.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP2138 (a bispecific antibody that binds to CLDN18.2 on tumor cells and T cells, helping the immune system attack the cancer)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with a specific type of stomach cancer that currently has limited targeted therapies.
What could go wrong
This is an early-phase 3 trial, and the added benefit of ASP2138 over standard care is not yet proven. There may be side effects from the combination therapy, including immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••